Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Autor: Dimopoulos, M.A. Leleu, X. Moreau, P. Richardson, P.G. Liberati, A.M. Harrison, S.J. Miles Prince, H. Ocio, E.M. Assadourian, S. Campana, F. Malinge, L. Sémiond, D. van de Velde, H. Yong, K.
Jazyk: angličtina
Rok vydání: 2021
Popis: The randomized, phase 3 ICARIA-MM study investigated isatuximab (Isa) with pomalidomide and dexamethasone (Pd) versus Pd in patients with relapsed/refractory multiple myeloma and ≥2 prior lines. This prespecified subgroup analysis examined efficacy in patients with renal impairment (RI; estimated glomerular filtration rate
Databáze: OpenAIRE